Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN918864) AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Researchat Helix BioPharma Corp., a developer of novel cancer therapeutics,will be presenting a scientific poster at the Fourth InternationalConference on Tumor Microenvironment, which runs from March 6th to10th in Florence, Italy. The conference, hosted by the...

Replidyne Phase II Pediatric Trial Meets Primary Objective

LOUISVILLE, Colo., March 06, 2007 /PRNewswire-FirstCall/ --Replidyne, Inc. announced today that it has completed its Phase IIclinical trial using faropenem medoxomil (faropenem) in pediatricpatients with acute otitis media (AOM), a common infection of themiddle ear. Initial analyses of the study results show that it metits primary objective to show that faropenem was effective ineradicatin...

DVT Awareness Survey Findings: Heart and Respiratory Patients

WASHINGTON, March 06, 2007 /PRNewswire/ -- Up to two millionAmericans are affected each year by DVT, with up to 600,000hospitalized. Its primary complication, pulmonary embolism (PE),claims up to 300,000 lives annually -- more than breast cancer andAIDS combined. People who suffer from cardiovascular disease may beat increased risk for DVT, because these factors also heighten thelikelihood...

Pozen Announces Positive Outcome for PA 325

Chapel Hill, N.C., March 6, 2007-Pozen Inc. (NASDAQ: POZN),today announced top-line results of its "Safer Aspirin" PA 325proof-of-concept study conducted during the fourth quarter of 2006.PA 325 is a patented formulation of 325mg of aspirin surrounded bya 20mg coating of an immediate release formulation of a proton pumpinhibitor. The PA 325, 28 day study, involved two groups of 40 subject...

Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings

CAMBRIDGE, Mass., March 06, 2007 /PRNewswire-FirstCall/ --Advanced Magnetics today announced that data from three completedPhase III multi- center clinical studies of ferumoxytol as anintravenous iron replacement therapeutic will be presented duringthe National Kidney Foundation (NKF) 2007 Spring Clinical Meetingstaking place April 10th through 14th in Orlando, Florida. Twoposters containi...

POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar 6, 2007 - POZEN Inc.(NASDAQ: POZN), today announced top-line results of its "SaferAspirin" PA 325 proof-of-concept study conducted during the fourthquarter of 2006. PA 325 is a patented formulation of 325mg ofaspirin surrounded by a 20mg coating of an immediate releaseformulation of a proton pump inhibitor. The PA 325, 28 day study, involved two group...

Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia

- 78 Percent of Patients Showed Complete Response or Reduction ofLesion Size by More than Fifty Percent - SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - NventaBiopharmaceuticals Corporation today announced the presentation ofpositive results from a clinical trial examining the safety andefficacy of pilot process HspE7, an investigational therapeuticvaccine for human papillomavirus (...

AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy

VIENNA, Austria and CHAPEL HILL, N.C., US, March 06, 2007/PRNewswire/ -- AOP Orphan Pharmaceuticals AG ("AOP Orphan") andLantibio, Inc. ("Lantibio") today announced positive final resultsfrom their placebo controlled, double-blinded Phase II clinicalstudy of Moli1901, an experimental compound to treat cysticfibrosis ("CF"). Moli1901 is being developed by AOP Orphan inEurope under a licensi...

Advanced Cell Technology's Ability to Rescue Vision in Blind Rats Noted in Scientific American

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar 5, 2007 - Advanced CellTechnology, Inc.'s (OTCBB: ACTC) ability to rescue vision in blindrats was noted in Scientific American's March 2007 issue as thelead story of its News Scan section. The full text of the article,which notes Advanced Cell's ability to "coax embryonic stem cellsto turn into transplantable retinal pigment epithelial (RPE)tissue," is...

Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology

TAMPA, Fla.--(BUSINESS WIRE)--Mar 7, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters atthe Annual Meeting of the American Academy of Allergy, Asthma, andImmunology from February 23 - 27, 2007 in San Diego, CA. Theposters discussed findings from a survey of 202 otolaryngologists(ENTs) and allergists in the U.S., U.K., France, and Germany on theburden of chroni...
[next]
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class designers of ... bring their novel lifesaving device for the everyday use of parents worldwide. It ... designed to read a child’s vital signs, and detect unusual symptoms or physical ...
(Date:4/24/2017)... NEW PORT RICHEY, Fla. (PRWEB) , ... April ... ... Disease Control and Prevention (CDC), rising prescription opioid overdose deaths now claim the ... (DEA) has slashed its civil case filings against drug manufacturers, distributors, pharmacies and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new ... is not known to have significant interactions with antiretroviral therapy (ART). Among ... levels and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening ...
(Date:4/24/2017)... KNOLLS, Calif. (PRWEB) , ... April 24, 2017 , ... ... health topics, but she has not found any of them to be very practical. ... actions to slowly and easily make changes in their health. It prompted her in ...
(Date:4/24/2017)... ... , ... “The Saint with Trin, and Omega Station”: a triple feature offering ... of published author, Chris Jackson. Chris Jackson grew up in Abilene, Texas. ... School District teaching English. He is heavily involved in the youth group of his ...
Breaking Medicine News(10 mins):
... June 17 ANSi Consulting (ANSi) proudly announces its ... South Jersey,s 25 fastest-growing private companies in the eight-county ... on June 11th, held at The Merion in Cinnaminson, ... (ANSi,s very first company award) on behalf of all ...
... 15 Years of Healthcare Experience to Growing North Texas Company ... Faro joins Dallas-based North American Spine ... years of healthcare experience, specializing in the development, growth and ... role, Faro will lead North American Spine,s efforts to build ...
... announced today that it has received approval from the U.S. ... Filled Capsules, a new treatment option indicated for relief of ... age or older). , , "Zipsor is a drug ... Officer of Xanodyne. "It is the first NSAID to ...
... Applied Medical, a new generation medical company, was ... healthcare alliance ,s first Innovation Celebration, an annual ... industry suppliers committed to innovation and improving patient outcomes. ... that bring a positive impact to healthcare delivery. The ...
... revealed that despite the drooping economy Scots men are opting ... moob removal surgery and finally getting their insecurities off their ... Cosmetic Surgery Group has revealed that despite the drooping economy ... by booking in for moob removal surgery and finally getting ...
... Surgical Company (Nasdaq: STAA ), a leading ... today announced the approval of the KS-Ni Preloaded Silicone ... , , The KS-Ni Preloaded Silicone IOL Injector ... silicone IOL through an incision size of 2.6 mm ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products:
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology:
... , SOUTH SAN FRANCISCO, Calif., July 21 ... company focused on innovative oncology therapies, today announced results from a ... chemotherapy agent and the Company,s lead product candidate. The Company worked ... this study, which is required for new chemical entities. , ...
... , , , ... , THE WOODLANDS, Texas, July 21 ... company focused on discovering and developing breakthrough treatments for human disease, announced ... Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) for ...
Cached Medicine Technology: